Development of Vancomycin Population Pharmacokinetic Models for Pediatric Patients Using a Real-World Web Application
Kazutaka Oda1,2, Kensuke Shoji3, Kazuaki Matsumoto4
1Department of Pharmacy, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto city, Kumamoto 860-8556, Japan.
Insights
A new population pharmacokinetic model for vancomycin dosing in Japanese children demonstrates excellent predictive performance. Two-point blood sampling is recommended for improved vancomycin clearance estimation in pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Pharmacokinetics
Background:
- The Japanese Society of Chemotherapy developed the practical area under the concentration-time curve (AUC)-guided therapeutic drug monitoring (PAT) application for vancomycin dosing.
- PAT has generated a large real-world pharmacokinetic database in Japan.
- Existing pediatric vancomycin models require optimization for Japanese children.
Purpose of the Study:
- To develop a population pharmacokinetic (popPK) model for Japanese pediatric vancomycin dosing.
- To compare the performance of the new model against existing models.
Main Methods:
- Utilized a real-world database from 1673 Japanese pediatric patients (aged 3 months+) collected via PAT.
- Performed population pharmacokinetic analysis using nonlinear mixed-effects modeling.
- Compared the developed model against 5 existing pharmacokinetic models.
Main Results:
- The developed popPK model showed strong a priori predictive performance for empirical vancomycin dosing (MPE: 0.2 μg/mL, MAPE: 5.6 μg/mL) with no bias.
- Graphical diagnostics confirmed optimal a priori prediction.
- Two-point vancomycin sampling yielded significantly different clearance estimates compared to one-point sampling in 18.1% of patients.
Conclusions:
- The developed popPK model is suitable for both empirical and Bayesian-guided vancomycin dosing in Japanese pediatric patients (3 months+).
- Two-point vancomycin sampling enhances clearance estimation accuracy and is recommended when feasible.
Background:
The Japanese Society of Chemotherapy developed practical area under the concentration-time curve (AUC)-guided therapeutic drug monitoring (PAT), a freely available web-based application widely used in Japan to support AUC-guided dosing of vancomycin. Its broad adoption has generated a substantial real-world pharmacokinetic database. Although PAT includes a preliminary pediatric model based on data from American children aged 3 months or older, that model requires further optimization. This study aimed to develop a population pharmacokinetic (popPK) model specifically for Japanese pediatric patients and to compare its performance with existing models.
Methods:
We utilized a real-world database collected through PAT between December 2022 and October 2024, comprising 1673 pediatric patients aged 3 months or older. Population pharmacokinetic analysis was performed using nonlinear mixed-effects modeling, with comparisons made against 5 existing models.
Results:
The developed model demonstrated strong a priori predictive performance for empirical vancomycin dosing, with a mean prediction error of 0.2 μg/mL and a mean absolute prediction error of 5.6 μg/mL. These results showed no apparent bias. Graphical diagnostics confirmed optimal a priori prediction in the developed model. A posteriori predictive performance-used for Bayesian posterior dosing-was similarly favorable across all models. Notably, 2-point sampling produced significantly different clearance estimates compared with 1-point sampling in 21 of 116 patients (18.1%).
Conclusions:
For Japanese pediatric patients aged 3 months or older, the developed popPK model is suitable for both empirical and Bayesian-guided vancomycin dosing. Two-point sampling improves the accuracy of clearance estimation and is recommended when feasible.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:12Analysis of Population Pharmacokinetic Data
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...